Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

ts are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether experimental pain models of pain, including the capsaicin model, are accurate in predicting efficacy of novel analgesics in early clinical trials, whether the results of any Phase II trial or other study of NGX426 will be consistent with the results of the study reported in this press release, whether TorreyPines will be able to complete any potential strategic or financing transaction on terms acceptable to TorreyPines' stockholders, how the volatile economic environment will affect TorreyPines' efforts to complete a strategic or financing transaction, whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical tri
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 /CNW/ - Aequus ... to announce that it has closed a brokered ... warrants for approximately C$3.7 million.  Cormark Securities Inc. ... in the Brokered Offering for a syndicate of ... PI Financial Corp. (collectively the "Agents"). Concurrently with ...
(Date:11/18/2014)... RPS Diagnostics (RPS®) – a ... announces its third annual partnership of the Centers ... About Antibiotics Week from November 17-23. , Get ... designed to highlight the coordinated efforts of CDC, ... for-profit partners to provide education about the importance ...
(Date:11/18/2014)... November 18, 2014 Alanda Software, ... Transparency Reporting solutions, announced today that a top ... its Consummate Providerâ„¢ solution in both the U.S. ... Global, SaaS based, Data Quality remediation portal, designed ... third party Providers improve their ability to capture, ...
(Date:11/18/2014)... 2014 Array Architects is proud of ... to the nation's hospitals and health systems. It is ... dedicating their careers to the advancement of both the ... her respective field, Laura Silvoy has been chosen to ... Winter Simulation Conference. , Laura will present her ...
Breaking Biology Technology:Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2
... Unprecedented collaboration between industry, academia, government and health providers ... ... SAN DIEGO, June 16 The unique connectivity, talent ... sciences,companies to Scotland in recent years will be on show ...
... Deloitte,s leading position in the life sciences ... ... Deloitte has announced today an,agreement to acquire Recombinant Capital, Inc. ... in the,acquisition is Recap,s unique database that provides more than 1,500,subscribers ...
... BOSTON, June 16 Scimitar Equity, LLC issues ... VOQP), entitled,"Robust Pipeline of Niche, Cancer Therapies with ... at website: http://www.scimitarequity.com ., VioQuest Pharmaceuticals ... a recognized leader in the successful development of,novel ...
Cached Biology Technology:Scotland Showcased at BIO as Dynamic, Global Life Sciences Hub 2Scotland Showcased at BIO as Dynamic, Global Life Sciences Hub 3Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm 2Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc. 2
(Date:11/6/2014)... because of metastasis, yet progress in preventing and ... "It,s been particularly challenging to design drugs that ... in systems biology at Harvard Medical School. ... they,ve already metastasized." , Gujral and colleagues have ... researchers better understand how metastasis begins. Their findings ...
(Date:11/5/2014)... great diversity in their ability to identify scents and ... in their perceptual evaluation of odors, with women outperforming ... , Sex differences in olfactory detection may play a ... to one,s perception of smell, which is naturally linked ... has been suggested to be cognitive or emotional, rather ...
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... of Medicine today presented the 2013 Gustav O. Lienhard ... control tobacco use have helped save millions from premature, ... in general medicine as well as his work to ... to present this award to a dedicated champion of ...
... that adult women with anorexia whose disorder is not ... basis. Even after conclusion of therapy, they continue to ... improved opportunities for successful therapy. However, one quarter of ... rapid results. These are the findings of the world,s ...
... California, where more than 80% of the United States, ... the impact of these vast production systems on groundwater ... 2013 issue of HortScience , changes in growers, ... increased strawberry yields in the region by 140% during ...
Cached Biology News:Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicine's 2013 Lienhard Award 2Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicine's 2013 Lienhard Award 3Leader of smoking cessation and tobacco prevention efforts receives Institute of Medicine's 2013 Lienhard Award 4Largest therapy trial worldwide: Psychotherapy treats anorexia effectively 2Largest therapy trial worldwide: Psychotherapy treats anorexia effectively 3Largest therapy trial worldwide: Psychotherapy treats anorexia effectively 4New research informs California strawberry production practices 2
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
... Enzymatic method stops PCR carry-over contamination, ... to degrade PCR products from previous ... acid templates, which improves amplification ,Optimized ... reagents and GeneAmp instrument systems , ...
... α-Amylase is a hydrolytic enzyme that ... mixture of glucose, maltose, maltotriose and,dextrins. ... fluids of the human,body are of ... are important enzymes for industry.4, The ...
... a-Amylase is an enzyme that ... mixture of maltose, maltotriose, and dextrins. ... of the human body is of,clinical ... states including,pancreatitis and diabetes; plant and ...
Biology Products: